http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
McGovern, David A.,Doorley, Gerard W.,Whelan, Aine M.,Parker, Anthony W.,Towrie, Michael,Kelly, John M.,Quinn, Susan J. Korean Society of Photoscience 2009 Photochemical & photobiological sciences Vol.8 No.4
The photophysical properties of 5'-guanosine monophosphate (5'-GMP) and polyguanylic acid {poly(G)} in $D_2O$ solutions of varying pH have been studied using picosecond transient infrared absorption spectroscopy. Whereas in neutral or weakly alkaline solution only the vibrationally excited electronic ground state of 5'-GMP is observed, in acidic solution the relatively long-lived ($229{\pm}20\;ps$) electronic excited state of protonated 5'-GMP, which possesses strong absorptions at 1517 and $1634\;cm^{-1}$, could be detected. The picosecond transient behaviour of polyguanylic acid in acidic solution is also very different from that of the polynucleotide in neutral solution due not only to the protonation of guanine moieties yielding the protonated excited state but because of the disruption of the guanine stacks which are present in the species in neutral solution.
Jeon, Hong Jin,Fava, Maurizio,Mischoulon, David,Baer, Lee,Clain, Alisabet,Doorley, James,DiPierro, Moneika,Cardoos, Amber,Papakostas, George I Clinical Neuroscience Publishers 2014 International clinical psychopharmacology Vol.29 No.6
<P>The aim of this study was to evaluate efficacy of ziprasidone monotherapy for major depressive disorder (MDD) with and without psychomotor symptoms. In accordance with the sequential parallel comparison design, 106 MDD patients (age 44.010.7 years; female, 43.4%) were recruited and a post-hoc analysis was carried out on 12-week double-blind treatment with either ziprasidone (40-160 mg/day) or placebo, divided into two phases of 6 weeks each to the assigned treatment sequences, drug/drug, placebo/placebo, and placebo/drug. Psychomotor symptoms were evaluated on the basis of the Mini-International Neuropsychiatric Interview at baseline. Efficacy assessments, on the basis of the 17-item Hamilton Depression Rating Scale (HDRS-17) and the Quick Inventory of Depressive Symptomatology Scale, Self-Rated (QIDS-SR), were performed every week throughout the trial. In phase I, ziprasidone monotherapy produced significant improvement in patients with psychomotor symptoms compared with placebo on the basis of HDRS-17 (F=5.95, P=0.017) and QIDS-SR (F=5.26, P=0.025) scores, whereas no significant changes were found in HDRS-17 (F=2.32, P=0.15) and QIDS-SR (F=3.70, P=0.074) scores in patients without psychomotor symptoms. In phase II, ziprasidone monotherapy produced no significant differences compared with placebo. In the pooled analysis, ziprasidone monotherapy showed significance according to QIDS-SR (Z=2.00, P=0.046) and a trend toward statistical significance according to the HDRS-17 (Z=1.66, P=0.10) in patients with psychomotor symptoms. Ziprasidone monotherapy may produce significant improvement compared with placebo in MDD patients with psychomotor symptoms.</P>